These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 24752603

  • 1. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J, Alsaker MD, Opdahl S, Engstrøm MJ, Tretli S, Haugen OA, Bofin AM, Vatten LJ, Asvold BO.
    Int J Cancer; 2014 Dec 01; 135(11):2678-86. PubMed ID: 24752603
    [Abstract] [Full Text] [Related]

  • 2. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women.
    Horn J, Opdahl S, Engstrøm MJ, Romundstad PR, Tretli S, Haugen OA, Bofin AM, Vatten LJ, Åsvold BO.
    Cancer Causes Control; 2014 Jul 01; 25(7):881-9. PubMed ID: 24789514
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.
    Clin Breast Cancer; 2012 Oct 01; 12(5):340-6. PubMed ID: 23040002
    [Abstract] [Full Text] [Related]

  • 4. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
    Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LS, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G.
    Curr Res Transl Med; 2016 Oct 01; 64(1):15-20. PubMed ID: 27140595
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N, Choi JY, Sung H, Chung S, Song M, Park SK, Han W, Lee JW, Kim MK, Yoo KY, Ahn SH, Noh DY, Kang D.
    Int J Cancer; 2014 Aug 01; 135(3):669-81. PubMed ID: 24916400
    [Abstract] [Full Text] [Related]

  • 6. Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women.
    Miyagawa Y, Miyake T, Yanai A, Murase K, Imamura M, Ichii S, Takatsuka Y, Ito T, Hirota S, Saito M, Kotoura Y, Miyauchi K, Fujimoto Y, Hatada T, Sasa M, Miyoshi Y.
    Breast Cancer; 2015 Jul 01; 22(4):399-405. PubMed ID: 24000037
    [Abstract] [Full Text] [Related]

  • 7. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.
    Eur J Surg Oncol; 2013 Mar 01; 39(3):260-5. PubMed ID: 23313014
    [Abstract] [Full Text] [Related]

  • 8. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 01; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G.
    Int J Cancer; 2019 Mar 15; 144(6):1251-1261. PubMed ID: 30367449
    [Abstract] [Full Text] [Related]

  • 12. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    Eur J Cancer; 2014 May 15; 50(8):1412-21. PubMed ID: 24675287
    [Abstract] [Full Text] [Related]

  • 13. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 May 15; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

  • 14. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.
    Oncology; 2012 May 15; 83(4):228-33. PubMed ID: 22907070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.
    JAMA; 2006 Jun 07; 295(21):2492-502. PubMed ID: 16757721
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.